Roche and its co-developer Halozyme reported that the European Commission has approved its marketing approval for the subcutaneous injectable form of its PD-L1 inhibitor Tecentriq (atezolizumab) for multiple cancer types – the first ever SC injectable PD-L1 cancer immunotherapy in the EU . This approval is NOT about how clinically efficacious Tecentriq is; we know it is. This approval is about making Tecentriq more accessible and easier for the patient, easier for the doctors and easier for the healthcare system – a genuine game changer. Read-out of data from the pivotal phase 1b/3 IMscin001 trial demonstrated comparable levels of subcutaneous atezolizumab in the blood and a similar safety and efficacy profile to that of the IV formulation. Treatment time will reduce by approximately 80%, with most injections taking between 4 to 8 minutes compared with 30 to 60 minutes for an intravenous (IV) infusion. Potentially outpatient and home SC shots are now realistic compared to booking hospital beds for an hour-long IV drip. A definite bonus for the patient, doctor and healthcare system.
- Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
- Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
- Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
- Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
- Amtagvi – first cellular therapy approval for unresectable melanoma